[go: up one dir, main page]

MA27845A1 - Composition pharmaceutique a teneur en lactate et utilisations de ladite composition - Google Patents

Composition pharmaceutique a teneur en lactate et utilisations de ladite composition

Info

Publication number
MA27845A1
MA27845A1 MA28632A MA28632A MA27845A1 MA 27845 A1 MA27845 A1 MA 27845A1 MA 28632 A MA28632 A MA 28632A MA 28632 A MA28632 A MA 28632A MA 27845 A1 MA27845 A1 MA 27845A1
Authority
MA
Morocco
Prior art keywords
lactate
pharmaceutical composition
per liter
millimoles per
containing pharmaceutical
Prior art date
Application number
MA28632A
Other languages
English (en)
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of MA27845A1 publication Critical patent/MA27845A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant 250 à 2 400 millimoles par litre de lactate ou d'acide lactique, 2 à 10 millimoles par litre de cation potassium et éventuellement 2 à 5 millimoles par litre de cation calcium. Ladite invention concerne également des utilisations pharmaceutiques de cette composition ainsi que des utilisations pharmaceutiques d'une composition présentant une concentration de lactate ou d'acide lactique comprise entre 250 et 2 400 millimoles par litre.
MA28632A 2003-05-01 2005-12-01 Composition pharmaceutique a teneur en lactate et utilisations de ladite composition MA27845A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01

Publications (1)

Publication Number Publication Date
MA27845A1 true MA27845A1 (fr) 2006-04-03

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28632A MA27845A1 (fr) 2003-05-01 2005-12-01 Composition pharmaceutique a teneur en lactate et utilisations de ladite composition

Country Status (30)

Country Link
US (1) US20080125488A1 (fr)
EP (2) EP1617834B1 (fr)
JP (1) JP5037937B2 (fr)
KR (1) KR101076059B1 (fr)
CN (1) CN1777416B (fr)
AR (1) AR043670A1 (fr)
AT (1) ATE340568T1 (fr)
AU (1) AU2004233904B2 (fr)
BR (1) BRPI0409867A (fr)
CA (1) CA2523740C (fr)
CY (1) CY1105880T1 (fr)
DE (1) DE602004002585T2 (fr)
DK (1) DK1617834T3 (fr)
EA (2) EA013846B1 (fr)
ES (1) ES2274438T3 (fr)
IL (1) IL171721A (fr)
MA (1) MA27845A1 (fr)
MX (1) MXPA05011532A (fr)
MY (1) MY140382A (fr)
NO (1) NO20055652L (fr)
NZ (1) NZ543201A (fr)
PL (1) PL1617834T3 (fr)
PT (1) PT1617834E (fr)
SG (1) SG160217A1 (fr)
SI (1) SI1617834T1 (fr)
TN (1) TNSN05275A1 (fr)
TW (1) TWI290045B (fr)
UA (1) UA86937C2 (fr)
WO (1) WO2004096204A1 (fr)
ZA (1) ZA200509684B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006341414A1 (en) * 2006-04-03 2007-10-11 Innogene Kalbiotech Pte Ltd Lactate and calcium containing pharmaceutical composition and uses thereof
RU2459620C2 (ru) 2007-03-30 2012-08-27 Лаккуре Аб Применение олигомеров молочной кислоты в лечении гинекологических расстройств
KR20120015295A (ko) * 2009-03-26 2012-02-21 풀매트릭스 인코퍼레이티드 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
EP2464346A1 (fr) 2010-08-30 2012-06-20 Pulmatrix, Inc. Méthodes de traitement de la mucoviscidose
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA3086367A1 (fr) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Poudres seches a cations metalliques monovalents pour inhalation
EP3470057B1 (fr) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Poudres sèches cationiques contenants un sel de magnésium
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
EP2819672A1 (fr) 2012-02-29 2015-01-07 Pulmatrix, Inc. Poudres sèches pouvant être inhalées
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
DK2879524T3 (en) * 2012-08-01 2016-12-12 Purac Biochem Bv Laktatpulver and manufacturing method thereof
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9500657B2 (en) 2012-10-25 2016-11-22 Run Them Sweet Llc Formulations containing labels for medical diagnostics
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
EP2754356A1 (fr) 2013-01-15 2014-07-16 Purac Biochem N.V. Procédé de production de nisine amélioré
EP2769630B1 (fr) 2013-02-26 2016-04-27 Purac Biochem N.V. Procédé de production de nisine amélioré
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
WO2015182815A1 (fr) * 2014-05-26 2015-12-03 한국생명공학연구원 Composition pharmaceutique pour la prévention et le traitement d'une maladie ischémique, contenant un promoteur de l'expression ou l'activité de ndrg3 en tant que substance active
CN109414036A (zh) 2016-07-07 2019-03-01 帝斯曼知识产权资产管理有限公司 获得油菜籽蛋白质分离物的方法以及由此获得的蛋白质分离物
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
WO2020163654A1 (fr) * 2019-02-06 2020-08-13 Paul Leo Mcgrane Greffes vasculaires biologiquement modifiées pour des résultats de chirurgie de dérivation améliorés
US20230113843A1 (en) * 2020-01-24 2023-04-13 Daniel Q. Barkey Compositions and methods for weight loss
WO2023114375A2 (fr) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Compositions d'acide lactique inhalables ou ingérables pour traitement d'une maladie pulmonaire chronique
CN116531358A (zh) * 2023-06-06 2023-08-04 中国医科大学附属第一医院 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用
EP4502147A1 (fr) 2023-07-31 2025-02-05 M2Rlab SL Procédé de polarisation de cellules en un nouveau phénotype m2 et utilisations desdites cellules polarisées m2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502274A (ja) * 1985-12-18 1988-09-01 ビ−チ，リチヤ−ド　エル Ｌ↓−乳酸および／またはピルビン酸アニオンを用いた流体式治療法
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
ES2157260T3 (es) * 1993-06-04 2001-08-16 Biotime Inc Solucion semejante a plasma.
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (fr) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Compositions hypertoniques d'arginine et procedes
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
IL171721A (en) 2012-05-31
WO2004096204A1 (fr) 2004-11-11
TNSN05275A1 (en) 2007-07-10
CN1777416A (zh) 2006-05-24
PL1617834T3 (pl) 2007-02-28
MY140382A (en) 2009-12-31
KR101076059B1 (ko) 2011-10-21
NO20055652D0 (no) 2005-11-30
HK1085942A1 (en) 2006-09-08
DE602004002585T2 (de) 2007-10-25
AU2004233904B2 (en) 2009-11-12
CN1777416B (zh) 2012-11-07
UA86937C2 (ru) 2009-06-10
BRPI0409867A (pt) 2006-05-16
EP1617834A1 (fr) 2006-01-25
EP1617834B1 (fr) 2006-09-27
EA013846B1 (ru) 2010-08-30
ZA200509684B (en) 2007-03-28
SI1617834T1 (sl) 2007-02-28
EA200501675A1 (ru) 2006-06-30
EA010948B1 (ru) 2008-12-30
EP1759695A1 (fr) 2007-03-07
JP5037937B2 (ja) 2012-10-03
CA2523740C (fr) 2012-05-15
TW200423923A (en) 2004-11-16
NO20055652L (no) 2006-02-01
NZ543201A (en) 2007-05-31
PT1617834E (pt) 2007-01-31
EA200801073A1 (ru) 2008-08-29
CA2523740A1 (fr) 2004-11-11
CY1105880T1 (el) 2011-02-02
AR043670A1 (es) 2005-08-03
KR20050119701A (ko) 2005-12-21
US20080125488A1 (en) 2008-05-29
TWI290045B (en) 2007-11-21
SG160217A1 (en) 2010-04-29
DE602004002585D1 (de) 2006-11-09
MXPA05011532A (es) 2006-05-31
AU2004233904A1 (en) 2004-11-11
DK1617834T3 (da) 2007-02-05
ES2274438T3 (es) 2007-05-16
JP2006525324A (ja) 2006-11-09
ATE340568T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
MA27845A1 (fr) Composition pharmaceutique a teneur en lactate et utilisations de ladite composition
BRPI0510619A (pt) preparação e cápsula contendo a mesma
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
TNSN01009A1 (fr) (+) - 6 - [amino - (6 - chloro - pyridine - 3 - yl) - (3 - methyl - 3h - imidazole - 4 - yl) - methyl ] - 4 - ( 3 - chloro-phenyl) -1- cyclopropylmethyl - 1h - quinoleine - 2 - one, procede pour sa preparation et composition la contenant
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
EP1624874A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete
TN2009000138A1 (fr) Biaryl-ether-urees
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
FR2869803A1 (fr) Particules activables, preparation et utilisations
MY138289A (en) Pharmaceutical compositions
AR067030A2 (es) Composiciones farmaceuticas
BRPI0411024A (pt) métodos para induzir a eritropoiese intensificada ou completa em um paciente, para tratar ou prevenir doenças, e para aumentar a produção da eritropoietina na presença de uma citocina em um paciente, uso de um composto, kit, e, composição farmacêutica
EP2172246A3 (fr) Méthodes pour le traitement de la maladie d'Alzheimer et l'amélioration cognitive
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
BR0312407A (pt) Fenilbenzamidas
BR0317696A (pt) Composição para branqueamento
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
Jhala et al. Mitigating effects of some antidotes on fluoride and arsenic induced free radical toxicity in mice ovary
MA58700B1 (fr) Souche de cutibacterium acnes et utilisations médicales associées
ATE406903T1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
MA29784B1 (fr) Combinaisons contenant dmxaa pour traiter le cancer
BR112023017376A2 (pt) Soluções oftálmicas
ATE255891T1 (de) Stabiles gabapentin, das mehr als 20 ppm chlor enthält